Filing Details

Accession Number:
0001209191-14-002646
Form Type:
4
Zero Holdings:
No
Publication Time:
2014-01-09 16:49:15
Reporting Period:
2014-01-07
Filing Date:
2014-01-09
Accepted Time:
2014-01-09 16:49:15
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1009356 Salix Pharmaceuticals Ltd SLXP Pharmaceutical Preparations (2834) 943267443
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1204286 P William Keane 8510 Colonnade Center Drive
Raleigh NC 27615
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2014-01-07 22,500 $18.87 57,740 No 4 M Direct
Common Stock Disposition 2014-01-07 22,500 $88.31 35,240 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Option to Buy Common Stock Disposition 2014-01-07 22,500 $0.00 22,500 $18.87
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2014-06-17 No 4 M Direct
Reported Derivative Holdings
Sec. Name Sec. Type Price Date Expiration Date Amount Remaning Holdings Nature of Ownership
Common Stock Option to Buy Common Stock $17.63 2015-06-09 15,000 15,000 Direct
Expiration Date Amount Remaning Holdings Nature of Ownership
2015-06-09 15,000 15,000 Direct
Footnotes
  1. The exercise and sale were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 26, 2013.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $87.93 to $88.88, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.
  3. Options are 100% vested.